The session will highlight a case study from Sub-Saharan Africa, demonstrating how KETI AIs technology has improved patient understanding and engagement
Disclosures: Erick Cruz Grave: Nothing to Disclose, Connie Chan: Nothing to Disclose, Michael Corwin: Corcept Therapeutics: Consultant, Richard Dean: Nothing to Disclose, Sandeep Dhaliwal: Nothing to Disclose, Maryam Yazdanfar: Nothing to Disclose, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support 2344 SIGNIFICANCE OF HETEROGENEOUS BILIARY EPITHELIAL SENESCENCE AS A POSSIBLE TARGET OF NEW THERAPIES IN PRIMARY BILIARY CHOLANGITIS Motoko Sasaki 1 Yasunori Sato 1 Yasuni Nakanuma 2 , 1 Kanazawa university, 2 Fukui Saiseikai Hospital Background: New therapeutic strategies are demanded for the patients with primary biliary cholangitis (PBC) showing inadequate response for ursodeoxycholic acid (UDCA) therapy
This helps maximize benefits while minimizing potential risks
Low IGF-1 (under 200 ng/mL) combined with a depressed GSH-to-GSSG ratio or elevated lipid peroxides suggests your body is struggling on two separate fronts
